Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3451838 in Treatment-Resistant Migraine
NCT04498910Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of LY3451838 in migraine, sponsored by Eli Lilly and Company. Started Nov 2020; status: completed.
02
Drugs
LY3451838
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04498910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498910.